Proton Pump Inhibitors in Pediatric Gastroesophageal Reflux Disease: A Systematic Review of Randomized Controlled Trials

Autor: Sara María Fernández-González, Ana Moreno-Álvarez, Alfonso Solar-Boga

Publikováno v: Children, Vol 11, Iss 3, p 296 (2024)

This systematic review was conducted with the objective of understanding the efficacy and safety of proton pump inhibitors (PPIs) in the pediatric population. We used PubMed to identify randomized controlled trials (RCTs) published between 1 June 201

Externí odkaz: https://doaj.org/article/acd1729668474152a83031064c3ede77

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

Autor: Paula Zapata-Cobo, Sara Salvador-Martín, Marta Velasco, Laura M. Palomino, Susana Clemente, Oscar Segarra, Ana Moreno-Álvarez, Ana Fernández-Lorenzo, Begoña Pérez-Moneo, Montserrat Montraveta, Cesar Sánchez, Mar Tolín, Inés Loverdos, María Jesús Fobelo, Victor Manuel Navas-López, Lorena Magallares, Ruth García-Romero, José Germán Sánchez-Hernández, Alejandro Rodríguez, Ferrán Bossacoma, María Jesús Balboa, Enrique Salcedo, María Sanjurjo-Sáez, Luis A. López-Fernández

Publikováno v: Pharmacological Research, Vol 194, Iss , Pp 106859- (2023)

Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate g

Externí odkaz: https://doaj.org/article/932b1c7582b3485494608f6bff4859d4

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease

Autor: Sara Salvador-Martín, Bartosz Kaczmarczyk, Rebeca Álvarez, Víctor Manuel Navas-López, Carmen Gallego-Fernández, Ana Moreno-Álvarez, Alfonso Solar-Boga, Cesar Sánchez, Mar Tolin, Marta Velasco, Rosana Muñoz-Codoceo, Alejandro Rodriguez-Martinez, Concepción A. Vayo, Ferrán Bossacoma, Gemma Pujol-Muncunill, María J. Fobelo, Antonio Millán-Jiménez, Lorena Magallares, Eva Martínez-Ojinaga, Inés Loverdos, Francisco J. Eizaguirre, José A. Blanca-García, Susana Clemente, Ruth García-Romero, Vicente Merino-Bohórquez, Rafael González de Caldas, Enrique Vázquez, Ana Dopazo, María Sanjurjo-Sáez, Luis A. López-Fernández

Publikováno v: Pharmaceutics, Vol 13, Iss 1, p 77 (2021)

Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF d

Externí odkaz: https://doaj.org/article/c7b5825a40164690902dde36eb3bffe4

Pharmacogenetics of trough serum anti‐TNF levels in paediatric inflammatory bowel disease

Autor: Oscar Segarra, Elena Aznal, Antonio Millán-Jiménez, Francisco J. Eizaguirre, María Jesús Balboa-Vega, Gemma Pujol-Muncunill, Alejandro Rodriguez-Martinez, Rafael González de Caldas, Concepción Alvarez-Vayo, Carmen Gallego-Fernández, Judith Abarca-Zabalía, Susana Clemente, Rosana Muñoz-Codoceo, Mar Tolin, Javier Viada, Víctor Manuel Navas-López, Ana Moreno-Álvarez, César Sánchez, María Sanjurjo-Sáez, Inés Loverdos, Lorena Magallares, José Germán Sánchez-Hernández, Sara Salvador-Martín, Alfonso Solar-Boga, Eva Martínez-Ojinaga, Ferrán Bossacoma, Luis A. López-Fernández, Vicente Merino-Bohórquez, R. García-Romero, José A. Blanca-García

Publikováno v: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

AIMS: Identifying DNA variants associated with trough serum anti-tumour necrosis factor (TNF) levels could predict response to treatment in inflammatory bowel disease (IBD). To date, no specific studies have been performed in children. The aim of thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d711886b67e537c5b8c73c0e9f0b3683
https://doi.org/10.1111/bcp.14400

Effects of an Extensively Hydrolyzed Formula Supplemented with Two Human Milk Oligosaccharides on Growth, Tolerability, Safety and Infection Risk in Infants with Cow's Milk Protein Allergy: A Randomized, Multi-Center Trial

Autor: Yvan, Vandenplas, Marta, Żołnowska, Roberto, Berni Canani, Siân, Ludman, Zsuzsanna, Tengelyi, Ana, Moreno-Álvarez, Anne E N, Goh, Maria Laura, Gosoniu, Bridget-Anne, Kirwan, Monika, Tadi, Ralf G, Heine, Cinnamon Study Investigator Group

Publikováno v: Nutrients, Vol 14, Iss 530, p 530 (2022)
Nutrients; Volume 14; Issue 3; Pages: 530

This randomized clinical trial (Registration: NCT03085134) assessed if an extensively hydrolyzed formula (EHF) supplemented with two human milk oligosaccharides (HMO) and reduced protein content (2.20 g/100 kcal) supports normal growth in infants wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9272ca10943c67ab13157fcc0134babb
https://pubmed.ncbi.nlm.nih.gov/35276889